{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031138","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.771006+00:00","generated_at":"2026-06-04T21:32:31.543596+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa reports Q4 2023 net loss $33.3M; cash into H1 2026; key pipeline milestones on track","bullets":["Net loss Q4 2023 $33.3M ($30.8M prior year); FY net loss $135.4M; cash $237M, runway into H1 2026.","MRT-2359 MYC-driven solid tumors Phase 1/2; recommended Phase 2 dose expected Q2 2024; Fast Track for SCLC and NSCLC.","MRT-6160 VAV1 MGD IND filing planned Q2 2024; Phase 1 SAD/MAD study start mid-2024.","MRT-8102 NEK7 program first development candidate nominated; IND submission targeted Q1 2025.","Entered Roche collaboration; $50M upfront, potential >$2B milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031138","json":"https://secwatch.observer/filing/0000950170-24-031138.json","markdown":"https://secwatch.observer/filing/0000950170-24-031138.md","text":"https://secwatch.observer/filing/0000950170-24-031138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/0000950170-24-031138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/glue-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:32:31.543596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"42b9314844675d497f18db340eecb6484de03365","claim":"Monte Rosa Therapeutics, Inc. reported financial results for full year and fourth quarter ended December 31, 2023.","evidence_excerpt":"Monte Rosa Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024031138/0000950170-24-031138-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year and fourth quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}